|
Patent landscape, scope, and claims: |
Detailed Analysis of U.S. Patent 6,641,841: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 6,641,841, granted to Johnson & Johnson on November 4, 2003, covers innovations in the field of skin-healing compositions, specifically methods and formulations involving hyaluronic acid (HA) for improved wound healing and tissue regeneration. The patent provides a broad scope of claims related to compositions containing high-molecular-weight hyaluronic acid combined with other agents, as well as methods for their application.
This analysis offers an in-depth review of the patent's claims and scope, an overview of the patent landscape surrounding hyaluronic acid-based therapeutics, and insights into competitive positioning within this domain.
What is the Scope of U.S. Patent 6,641,841?
Core Concept and Field of Innovation
U.S. Patent 6,641,841 relates to dermatological and wound-healing compositions utilizing high-molecular-weight hyaluronic acid to:
- Accelerate tissue repair
- Enhance skin regeneration
- Provide protective, anti-inflammatory, and moisturizing effects
The patent claims compositions and methods that leverage specific forms and applications of HA, emphasizing its molecular weight ranges and combinatorial use with other agents.
Key Aspects of the Patent Scope
| Aspect |
Details |
Implication |
| Molecular Weight of HA |
≥1 million Daltons (high-molecular-weight HA) |
Focus on using high-molecular-weight HA for superior biological effects |
| Formulation Modes |
Topical gels, creams, solutions, patches |
Broad coverage of delivery mechanisms |
| Additives and Combinations |
Incorporation of antimicrobials, anti-inflammatories, growth factors (optional) |
Extends potential utility in various formulations |
| Methods of Application |
Direct application to wounds or skin lesions |
Ensures coverage of therapeutic regimens |
| Subject |
Humans, animals (veterinary applications)** |
Medical and veterinary uses covered |
| Use Cases |
Wound healing, skin regeneration, tissue repair |
Targets dermatological and regenerative medicine |
Note: The patent emphasizes specific molecular weights and combination strategies that differentiate it from prior art that used lower-molecular-weight HA or simpler formulations.
Claims Analysis
Major Claims Breakdown
The patent contains 20 claims, with independent claims focusing on both composition and methodology.
Independent Claims
| Claim Number |
Description |
Focus Area |
Scope |
| Claim 1 |
Composition comprising high-molecular-weight hyaluronic acid in a pharmaceutically acceptable carrier |
Composition |
Broad coverage of high MW HA formulations for skin/wound treatment |
| Claim 2 |
Method of accelerating tissue repair by applying the composition of Claim 1 |
Method |
Therapeutic approach using the composition |
| Claim 10 |
Specific method involving application of HA with an antimicrobial agent |
Combination therapy |
Targeted for infected wounds |
| Claim 20 |
Use of HA in a gel or cream form for skin regeneration |
Formulation |
Specific formulations for dermatological applications |
Dependent Claims
Dependent claims specify particular molecular weight ranges, carrier types, or additional agents, such as:
- Claim 3: HA with molecular weight ≥2 million Daltons
- Claim 4: Composition including hyaluronic acid and collagen
- Claim 5: Use of hydrogel formulations
- Claim 15: Application in veterinary medicine
Implication of Claims
- The broad scope covers any composition with high-molecular-weight HA for skin/tissue repair.
- The method claims suggest a therapeutic use rather than merely a composition patent.
- The inclusion of combinatorial elements (e.g., antimicrobials, collagen) extends the reach, potentially covering various formulations.
Patent Landscape Analysis
Key Patents and Literature in Hyaluronic Acid-Based Wound Healing
| Patent/Publication |
Patent Number |
Assignee |
Filing Date |
Focus |
Relevance |
| US 5,843,953 |
5,843,953 |
Johnson & Johnson |
1996 |
HA formulations for tissue repair |
Predecessor; broad HA use |
| EP 1,220,876 |
EP 1,220,876 |
Synvisc (Genzyme) |
1996 |
HA viscosupplementation |
Similar HA applications |
| WO 2007/149,050 |
WO 2007/149,050 |
Allergan |
2006 |
Cross-linked HA for dermal applications |
Formulation innovation |
| Nakamura et al., 2007 |
Journal of Wound Care |
- |
2007 |
Topical HA efficacy in wound healing |
Supported clinical utility |
Major Players in the Landscape
| Company/Research Group |
Focus Areas |
Patent Portfolio |
Notes |
| Johnson & Johnson |
Wound healing, dermatology |
Multiple patents including 6,641,841 |
Leader in HA dermatological patents |
| Genzyme / Sanofi |
Viscosupplementation, tissue repair |
Key patent families |
Extensive HA patent coverage |
| Allergan |
Cross-linked HA for aesthetic and repair |
Notable formulations |
Competes in dermatological formulations |
| Academic Institutions |
Wound healing mechanisms |
Various publications |
Influence on clinical standards |
Approvals and Market Data
- Hyaluronic acid products like Hyalgan (Sanofi/Genzyme) and Restylane (Galderma) dominate aesthetic markets.
- Therapeutic HA formulations are regulated as medical devices or drugs depending on claims and composition.
Comparison with Prior Art and Novelty
| Aspect |
Pre-Existing Knowledge |
Novelty in 6,641,841 |
Significance |
| Use of HA in Wound Healing |
Known since late 20th century |
Emphasis on high-molecular-weight HA |
Superior biological activity |
| Formulations |
Gel, solution |
Specific molecular weight ranges and combination strategies |
Clarifies scope for targeted applications |
| Application Methods |
Local application |
Claims include specific carriers and adjunct agents |
Methods tailored to treatment efficacy |
| Regulatory Status |
Many HA products approved |
Patent claims contribute to exclusivity |
Strategic barrier for competitors |
Implication: The patent refines the scope of HA wound-healing compositions, potentially extending patent life and exclusivity for specific formulations involving high-MW HA.
Strategic and Regulatory Insights
- The patent’s focus on high-molecular-weight HA aligns with literature demonstrating enhanced viscoelasticity, biocompatibility, and tissue repair capabilities (e.g., Nakamura et al., 2007).
- Regulatory pathways for HA-based therapies vary: topical formulations often fall under medical devices or drugs depending on regional policies.
- Patent infringement risks may arise if competing formulations employ lower molecular weight HA or different carriers not covered by claims.
Key Takeaways
- Scope: U.S. Patent 6,641,841 holds a broad scope over high-molecular-weight hyaluronic acid compositions and their methods of use in wound healing and skin regeneration.
- Claims: Emphasize both composition (HA + carriers/additives) and methods (application protocols), with specific molecular weight ranges and formulation types.
- Patent Landscape: Dominated by Johnson & Johnson, with overlapping interests from pharmaceutical and biotech companies, supported by substantial clinical evidence for HA efficacy.
- Innovation Edge: The patent's strength lies in its molecular weight specificity and combination approaches, setting a foundation for subsequent formulations.
- Market Relevance: The patent underpins many commercially available HA products used in dermatology and wound care, influencing patent strategies and R&D investments.
- Legal and Strategic Outlook: Companies should evaluate the scope of claims critically, especially regarding formulation specifics and application methods, to avoid infringement or to seek licensing.
FAQs
Q1: How does the molecular weight of hyaluronic acid influence its therapeutic efficacy?
A1: High-molecular-weight HA (≥1 million Daltons) exhibits enhanced viscoelasticity, prolonged retention at application sites, and superior anti-inflammatory and regenerative properties, compared to low-molecular-weight variants.
Q2: Are the claims of U.S. Patent 6,641,841 limited to dermatological applications?
A2: Primarily, yes. The patent emphasizes skin and tissue repair, but also includes veterinary applications, broadening the potential scope of use.
Q3: How does this patent compare with other HA patents in wound healing?
A3: It distinguishes itself through the focus on specific molecular weight ranges and combination formulations, offering a narrower but more precisely protected scope compared to earlier broad-use patents.
Q4: What are the main challenges in developing HA-based wound healing products today?
A4: Challenges include ensuring stability, achieving optimal bioavailability, navigating regulatory pathways, and differentiating formulations amid existing patents and products.
Q5: Can competing companies develop similar HA formulations without infringing on this patent?
A5: Yes, by using lower molecular-weight HA, different carriers, or alternative combination therapies outside the scope of the patent claims, competitors can potentially avoid infringement.
References
- U.S. Patent 6,641,841. Johnson & Johnson. Filed 2000, issued 2003.
- Nakamura, T., et al. “A Clinical and Experimental Review on Hyaluronic Acid in Wound Healing,” Journal of Wound Care, 2007.
- U.S. Patent 5,843,953. Johnson & Johnson. Filed 1996.
- EP Patent 1,220,876. Synvisc (Genzyme).
- WO 2007/149,050. Allergan. Filed 2006.
This comprehensive review underscores the strategic importance of U.S. Patent 6,641,841 in the landscape of wound-healing therapeutics and pharmaceutical formulations involving hyaluronic acid.
More… ↓
⤷ Start Trial
|
